| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $3.0M-92.6% | $40.4M-46.9% | $76.1M-57.4% | $178.7M | ||||||||||||
| Accounts receivable | $1.8M+349.9% | $407K-98.4% | $25.8M+842.6% | $2.7M | ||||||||||||
| Related party note receivable from MiNK Therapeutics, Inc. | $5.2M | $0 | — | — | ||||||||||||
| Prepaid expenses | $785K-66.1% | $2.3M-71.4% | $8.1M-41.4% | $13.8M | ||||||||||||
| Assets held for sale | $121.6M | $0 | — | — | ||||||||||||
| Other current assets | $1.1M-54.9% | $2.4M+1.8% | $2.4M-25.7% | $3.2M | ||||||||||||
| Total current assets | $133.4M+192.8% | $45.6M-59.5% | $112.4M-47.3% | $213.1M | ||||||||||||
| Property, plant and equipment, net of accumulated amortization and depreciation of $47,468 and $72,553 at December 31, 2025 and 2024, respectively | $15.5M-87.1% | $120.1M-10.0% | $133.4M+0.3% | $133.0M | ||||||||||||
| Operating lease right-of-use assets | $7.7M-71.6% | $27.3M-7.8% | $29.6M-5.3% | $31.3M | ||||||||||||
| Goodwill | $24.1M+0.0% | $24.1M-2.6% | $24.7M-2.9% | $25.5M | ||||||||||||
| Acquired intangible assets, net of accumulated amortization of $17,325 and $16,986 at December 31, 2025 and 2024, respectively | $3.0M-10.0% | $3.4M-23.5% | $4.4M-29.2% | $6.2M | ||||||||||||
| Equity method investment in MiNK Therapeutics, Inc. | $24.3M | $0 | — | — | ||||||||||||
| Other long-term assets | $3.3M-43.3% | $5.8M-37.5% | $9.3M+109.7% | $4.5M | ||||||||||||
| Total assets | $226.8M+0.2% | $226.3M-27.9% | $313.9M-24.1% | $413.6M | ||||||||||||
| Current portion, long-term debt | $44.7M+1555.1% | $2.7M+1747.9% | $146K-74.6% | $575K | ||||||||||||
| Current portion, liability related to sale of future royalties and milestones | $109.3M-2.4% | $112.0M-15.5% | $132.5M+58.7% | $83.5M | ||||||||||||
| Current portion, deferred revenue | $0-100.0% | $31K+72.2% | $18K-99.9% | $12.3M | ||||||||||||
| Current portion, operating lease liabilities | $1.0M-57.7% | $2.4M-5.5% | $2.6M+33.1% | $1.9M | ||||||||||||
| Accounts payable | $83.0M+35.0% | $61.5M+0.0% | $61.4M+50.1% | $40.9M | ||||||||||||
| Accrued liabilities | $34.2M-2.1% | $35.0M-22.8% | $45.3M+18.4% | $38.3M | ||||||||||||
| Liabilities held for sale | $50.7M | — | — | — | ||||||||||||
| Other current liabilities | $529K-93.2% | $7.8M-43.8% | $13.9M+21.5% | $11.5M | ||||||||||||
| Total current liabilities | $323.5M+46.1% | $221.4M-13.5% | $255.9M+35.4% | $189.0M | ||||||||||||
| Long-term debt, net of current portion | $0-100.0% | $30.5M+138.7% | $12.8M+1.5% | $12.6M | ||||||||||||
| Liability related to sale of future royalties and milestones, net of current portion | $169.7M-24.4% | $224.4M+80.2% | $124.6M-33.7% | $187.8M | ||||||||||||
| Deferred revenue, net of current portion | $1.1M+0.0% | $1.1M+0.0% | $1.1M+0.0% | $1.1M | ||||||||||||
| Operating lease liabilities, net of current portion | $10.1M-81.5% | $54.6M-12.7% | $62.5M-1.3% | $63.3M | ||||||||||||
| Other long-term liabilities | $259K-64.9% | $738K-86.4% | $5.4M-63.1% | $14.7M | ||||||||||||
| Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2025 and 2024; 35,320,397 shares and 23,634,670 shares issued and outstanding at December 31, 2025 and 2024, respectively | $353.00+49.6% | $236.00+19.8% | $197.00-93.6% | $3056.00 | ||||||||||||
| Additional paid-in capital | $1.91B+2.9% | $1.86B+3.4% | $1.80B+9.2% | $1.64B | ||||||||||||
| Accumulated other comprehensive loss | -$439K+68.6% | -$1.4M-46.4% | -$955K-204.4% | $915K | ||||||||||||
| Accumulated deficit | -$2.18B+0.0% | -$2.18B-11.6% | -$1.96B-14.4% | -$1.71B | ||||||||||||
| Total stockholders' deficit attributable to Agenus Inc. | -$271.1M+16.9% | -$326.4M-103.6% | -$160.3M-161.6% | -$61.3M | ||||||||||||
| Non-controlling interest | -$6.8M-133.8% | $20.0M+67.0% | $11.9M+87.4% | $6.4M | ||||||||||||
| Total stockholders' deficit | -$277.9M+9.3% | -$306.4M-106.5% | -$148.4M-170.3% | -$54.9M | ||||||||||||
| Total liabilities, convertible preferred stock and stockholders' deficit | $226.8M+0.2% | $226.3M-27.9% | $313.9M-24.1% | $413.6M | ||||||||||||
| Related Parties [Member] | ||||||||||||||||
| Due from related parties (MiNK Therapeutics, Inc.) | $15.4M | $0 | — | — | ||||||||||||
| Series A-1 convertible preferred stock [Member] | ||||||||||||||||
| Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at December 31, 2025 and 2024; liquidation value of $34,317 and $34,101 at December 31, 2025, and 2024, respectively | $0 | $0 | $0 | $0 | ||||||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.